Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pediatric Transplants

Allo-SCT using BU, CY and melphalan for children with AML in second CR

Abstract

Based on the results from the AML-BFM 98 trial, hematopoietic SCT (HSCT) is recommended for children with AML in second CR only. Here, we retrospectively analyze interphase data of children who underwent HSCT after myeloablative conditioning with BU, CY, and melphalan (BuCyMel) for AML in second remission (CR2) between 1998 and 2009. Out of 152 children, transplant data were available on 109 individuals. Sixty out of 109 children (55%) received BuCyMel. Median age at HSCT was 12.2 years (range 3.0; 18.3). GVHD prophylaxis mostly consisted of CsA and short term MTX with or without antithymocyte globulin. Matched-sibling donors were used for 6/60 analyzed recipients, the remainder either received grafts from matched unrelated (30/60) or mismatched donors. OS after 5 years was 62% (s.e. 6%), relapse incidence 35% (18/60 children) and treatment-related mortality accounted for 12% (7/60) of fatal events. In conclusion, even taking into account possible selection bias in this retrospective analysis, HSCT in CR2 using BuCyMel resulted in a respectable OS. Based on this data the prospective, controlled and centrally monitored AML SCT-BFM 2007 trial has started to recruit patients in January 2010 aiming to generate valid outcome data for further strategy decisions.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Klusmann JH, Reinhardt D, Zimmermann M, Kremens B, Vormoor J, Dworzak M et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97: 21–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

    PubMed  Google Scholar 

  3. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951. J Clin Oncol 2003; 21: 2940–2947.

    Article  CAS  PubMed  Google Scholar 

  4. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377–4385.

    Article  CAS  PubMed  Google Scholar 

  5. Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229–236.

    Article  PubMed  Google Scholar 

  6. Sander A, Zimmermann M, Dworzak M, Fleischhack G, von Neuhoff C, Reinhardt D et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422–1428.

    Article  CAS  PubMed  Google Scholar 

  7. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  8. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  9. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994; 12: 1217–1222.

    Article  CAS  PubMed  Google Scholar 

  10. Pession ArC, Putti MC, Masetti R, Casale F, Fagioli F, Nigro LL et al. Results of the AIEOP AML 2002/01 study for treatment of children with acute myeloid leukemia. Blood, [Abstract] 2009; 114: 13.

    Google Scholar 

  11. Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011; 25: 455–462.

    Article  CAS  PubMed  Google Scholar 

  12. Locatelli F, Pession A, Bonetti F, Maserati E, Prete L, Pedrazzoli P et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994; 8: 844–849.

    CAS  PubMed  Google Scholar 

  13. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324–2328.

    CAS  PubMed  Google Scholar 

  14. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 1995; 17: 427–433.

    Article  CAS  PubMed  Google Scholar 

  15. Kroger N, Zabelina T, Sonnenberg S, Kruger W, Renges H, Stute N et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 711–716.

    Article  CAS  PubMed  Google Scholar 

  16. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R et al. Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant 2011; 46: 192–199.

    Article  CAS  PubMed  Google Scholar 

  17. Phillips GL, Shepherd JD, Barnett MJ, Lansdorp PM, Klingemann HG, Spinelli JJ et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 1991; 9: 1880–1888.

    Article  CAS  PubMed  Google Scholar 

  18. Corringham R, Gilmore M, Prentice HG, Boesen E . High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 1983; 52: 1783–1787.

    Article  CAS  PubMed  Google Scholar 

  19. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D et al. High-dose N,N′,N′-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (1 Suppl 3): 2–6.

    CAS  PubMed  Google Scholar 

  20. Wolff SN, Fer MF, McKay CM, Hande KR, Hainsworth JD, Greco FA . High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. J Clin Oncol 1983; 1: 701–705.

    Article  CAS  PubMed  Google Scholar 

  21. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990; 75: 27–32.

    CAS  PubMed  Google Scholar 

  22. Locatelli F, Zecca M, Messina C, Rondelli R, Lanino E, Sacchi N et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 2002; 16: 2228–2237.

    Article  CAS  PubMed  Google Scholar 

  23. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ et al. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 1996; 2: 1481–1487.

    CAS  PubMed  Google Scholar 

  24. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915–924.

    Article  CAS  PubMed  Google Scholar 

  25. Ryu SG, Lee JH, Choi SJ, Lee YS, Seol M, Hur EH et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1095–105.

    Article  CAS  PubMed  Google Scholar 

  26. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010; 3: 36.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We especially thank the AML-BFM study group, study nurses and physicians for their tremendous support collecting patient data. Rita Beier was supported by a grant of the German Ministry for Research and Education (BMBF, IFB-TX, Project 91). We thank Kirsten Mischke and Katja Arens for expert data management.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M G Sauer.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beier, R., Albert, M., Bader, P. et al. Allo-SCT using BU, CY and melphalan for children with AML in second CR. Bone Marrow Transplant 48, 651–656 (2013). https://doi.org/10.1038/bmt.2012.204

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.204

Keywords

This article is cited by

Search

Quick links